Research Study Search Tool

Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?

| More

Search Results: Treatment + Breast Cancer + Stage 4 (5 results)

Here are some research studies that may be enrolling patients like you. Please check with the study contact and your health care provider to confirm your eligibility and see if the study is right for you. Note, our search tool may not be comprehensive and additional research resources can be found here.

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Treatment:
Breast
Ovarian
Prostate

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

The purpose of the study is to examine the anti-tumor activity and safety of the immuno-onology agent, avelumab in combination with the PARP inhibitor, talazoparib in patients with locally advanced  or metastatic triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast cancer, recurrent platinum sensitive ovarian cancer, castration resistant prostate cancer (CRPC) solid, non-small cell lung cancer (NSCLC), and urothelial cancer (UC). The study is also open to people with other advanced solid tumors with a BRCA or ATM gene defect

A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations

Treatment:
Breast
Ovarian
Pancreatic
Prostate

A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations

This is an early-phase (phase 1) study on a new type of platinum chemotherapy called BTP-114, for patients with advanced cancer caused by a BRCA mutation or other mutation in genes associated with repairing DNA damage. The study is open to patients with breast, ovarian, pancreatic, prostate and other solid tumor cancers.  

Talazoparib Beyond BRCA (TBB) Trial

Treatment:
Breast

Talazoparib Beyond BRCA (TBB) Trial

The goal of the study is to evaluate the anti-cancer activity of Talazoparib (a type of treatment known as a PARP inhibitor) in patients with advanced breast cancer with specific genetic mutations based on a blood, saliva, or tumor test. See the clinicaltrials.gov listing for additional information. 

Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer

Treatment:
Breast

Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer

This study is for with people with advanced breast cancer and a BRCA mutation or triple-negative breast cancer. This study is open to people with spread of the cancer to their brain or other places in their body. The study will compare whether adding the PARP inhibitor veliparib to the chemotherapy cisplatin improves response over chemotherapy alone. Veliparib is a PARP inhibitor that inhibits the ability of cancer cell to fix DNA damage caused by chemotherapy.  This drug combination could be important for patients who have brain metastasis because veliparib and cisplatin both cross the blood brain barrier. The goal of this study is to treat metastatic breast cancer within the brain and outside of the brain (i.e. in other parts of the body) at the same time. 

This study is important because most studies for people with metastatic breast cancer exclude patients who have spread to the brain. 

 

Pembrolizumab in Advanced BRCA-mutated Breast Cancer

Treatment:
Breast

Pembrolizumab in Advanced BRCA-mutated Breast Cancer

 

This trial will evaluate the use of immunotherapy in people with advanced breast cancer associated with a BRCA mutation. The main objective is to examine overall response rate of pembrolizumab (immunotherapy) single agent therapy in advanced BRCA-mutated breast cancer.

Visit clinicaltrials.gov for more information. 

Additional Results on Clinicaltrials.gov: Treatment + Breast Cancer + Stage 4

247 Results

Clinical Trial Official Title
NCT03524170 RACHEL1: Radiation and CHEckpoint bLockade Trial in Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT03051672 Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC
NCT03004183 SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
NCT02422498 Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy
NCT01697293 Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer
NCT02892734 Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
NCT03473639 A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy
NCT03012230 Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer
NCT03362060 PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
NCT03567720 Intratumoral Tavo and Pembro in Patients With Inoperable Locally Advanced or Metastatic TNBC
NCT02479230 Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients
NCT01758445 Proton Radiation for Stage II/III Breast Cancer
NCT03544125 Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer
NCT01621906 18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain
NCT02364557 Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer
NCT03112590 Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
NCT02536794 MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer
NCT03106415 Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer
NCT02751528 QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer
NCT02696759 Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer
NCT01897441 Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer
NCT02639026 Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
NCT03272334 Her2-BATS and Pembrolizumab in Metastatic Breast Cancer
NCT02720185 Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
NCT03135171 Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab
NCT03012477 CISPLATIN + AZD-1775 In Breast Cancer
NCT02411656 MK-3475 for Metastatic Inflammatory Breast Cancer (MIBC)
NCT03379428 Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
NCT03718455 Evaluation of Magseed as Localization Device for Biopsy Proven Metastatic Axillary Lymph Nodes
NCT03237572 Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer
NCT01960803 Lumpectomy Followed By Intraoperative Electron Radiation Therapy (IOERT)
NCT03179904 FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients With HER2 Positive Advanced Breast Cancer
NCT02603341 Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
NCT01724606 Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)
NCT02453620 Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
NCT03106077 Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC)
NCT02774681 Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis
NCT02066532 Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
NCT03430518 Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
NCT03202316 Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Recurrent/Metastatic Inflammatory Breast Cancer
NCT03093350 TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer
NCT03566485 Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
NCT01618357 Pre-Operative Radiation and Veliparib for Breast Cancer
NCT03328026 Combination Study of SV-BR-1-GM in Combination With Pembrolizumab
NCT02530489 Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a Pdl-1 Inhibitor in Patients With Triple Negative Breast Cancer
NCT03432741 Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
NCT02792114 T-Cell Therapy for Advanced Breast Cancer
NCT03316586 A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer
NCT01676753 Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer
NCT03449238 Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
NCT00625417 Optical Spectroscopy in Evaluating Tumor Margins in Patients Who Have Undergone Surgery for Breast Tumors
NCT01622868 Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
NCT02013492 Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
NCT03428802 Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
NCT03051659 A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer
NCT02981303 Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer
NCT03535701 Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer
NCT02778685 Pembrolizumab, Letrozole, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
NCT03256344 A Safety Study of Talimogene Laherparepvec Combined With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
NCT02599363 A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer
NCT01730118 Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing
NCT03025035 Pembrolizumab in Advanced BRCA-mutated Breast Cancer
NCT03037723 Prone Whole-Breast RadiationTherapy Versus Supine Whole-Breast Radiation Therapy Imaging
NCT03101748 A Phase 1b Study of Neratinib, Pertuzumab and Trastuzumab With Taxol (3HT) in Primary Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC
NCT02608216 [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
NCT02971761 Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer
NCT01953588 Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
NCT03417544 Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
NCT02953860 Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
NCT02632071 ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer
NCT03193853 TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
NCT03166085 PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer
NCT02157051 Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
NCT03674827 A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
NCT03121352 Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer
NCT03262935 SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
NCT02824575 Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
NCT01792726 A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.
NCT02776917 Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer
NCT01376505 Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
NCT02876107 A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC)
NCT03218826 PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
NCT02492711 Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
NCT02188745 ER Reactivation Therapy for Breast Cancer
NCT02913430 Phase II Treatment of Metastatic Breast Cancer With Fulvestrant or Tamoxifen
NCT03324802 Hypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After Surgery
NCT02401347 Phase II Talazoparib in BRCA1 +BRCA2 Wild-Type &Triple-Neg /HER2-Negative Breast Cancer /SolidTumors
NCT02898207 Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
NCT03321981 MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer
NCT03393845 Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
NCT02706392 Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
NCT03184558 Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
NCT02648477 Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
NCT01976169 Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)
NCT02390427 Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
NCT03429101 A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer
NCT03125928 Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
NCT03113825 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
NCT03217747 Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
NCT03018080 Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer
NCT03206203 Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer
NCT02834403 L-NMMA Plus Docetaxel in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
NCT02672475 Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
NCT02942355 Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer
NCT02624700 2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
NCT02111850 T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
NCT03344536 A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer
NCT02657343 An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.
NCT03294694 Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
NCT03412877 Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer
NCT01446016 Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)
NCT02734290 Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
NCT03414684 Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
NCT03281720 Selective Image Guided Resection of Pathologically Documented Axillary Lymph Node Metastases
NCT03377387 Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
NCT03616587 Study of AZD9833 Alone or in Combination With Palbociclib in Women With Advanced Breast Cancer
NCT03032107 A Study Of Pembrolizumab In Combination With Trastuzumab-DM1
NCT02755272 A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
NCT02971748 A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy
NCT03007979 Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
NCT01552434 Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
NCT01174121 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT02871791 Palbociclib With Everolimus + Exemestane In BC
NCT03310957 Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
NCT03139435 Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer
NCT03364348 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
NCT01554371 Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
NCT02738866 Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor
NCT03471663 A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer
NCT03709082 Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
NCT02595320 Capecitabine in Metastatic Breast and GI Cancers
NCT02860000 Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
NCT01967823 T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
NCT03439735 Determinants of Resistance to First-line Therapy With an AI and Palbociclib for HR+ MBC
NCT03190967 T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
NCT02395627 Reversing Therapy Resistance With Epigenetic-Immune Modification
NCT01969643 A Safety Study of SGN-LIV1A in Breast Cancer Patients
NCT03286842 To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
NCT03284957 Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer
NCT03225547 Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
NCT03238196 Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
NCT03344965 Olaparib In Metastatic Breast Cancer
NCT03414658 The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
NCT02614794 Phase 2 Study of Tucatinib vs Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
NCT02384746 Phase I Study of the Combination of MLN9708 and Fulvestrant
NCT02954874 Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
NCT03560531 A Study of ZN-c5 in Subjects With Breast Cancer
NCT03326102 Oral Paclitaxel Efficacy Safety and PK in Recurrent and metAstatic Breast Cancer
NCT02152943 Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
NCT03095352 A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
NCT03304080 Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast
NCT03289039 Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
NCT03523585 DS-8201a Versus Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Pretreated With Prior Standard of Care [DESTINY-Breast02]
NCT03241810 Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer
NCT02422641 Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
NCT02632045 Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer
NCT02605486 Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)
NCT03128619 Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
NCT03650348 PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
NCT02692755 Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer
NCT03529110 DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
NCT02595905 Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
NCT02668666 Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
NCT03300843 Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
NCT02393794 Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
NCT03330847 To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
NCT03319459 FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
NCT03493854 A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
NCT01920061 A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
NCT02384239 A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer
NCT02236000 A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
NCT03326674 Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, MBC (CONTESSA)
NCT03633331 Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
NCT02779751 A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
NCT02947685 Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
NCT02915744 A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
NCT01670877 Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
NCT03050398 A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
NCT03337724 A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
NCT03584009 A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
NCT03054363 Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
NCT01805076 MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
NCT03125902 A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
NCT03424005 A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)
NCT03387085 QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
NCT02684032 A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
NCT03147287 Palbociclib After CDK and Endocrine Therapy (PACE)
NCT03538028 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
NCT01989546 Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
NCT02964507 Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer
NCT03012100 Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
NCT03167619 Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)
NCT02849496 Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
NCT03332797 A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
NCT03685591 PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
NCT03096418 Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
NCT03056755 Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant
NCT03719326 A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer and Gynecologic Malignancies
NCT02788981 Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
NCT02830724 Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT01037790 PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER
NCT02910219 Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients
NCT03006172 To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
NCT03499899 A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer
NCT02983045 A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) or in Combination With Nivolumab and Anti-CTLA4 Antibody (Ipilimumab) in Patients With Select Advanced or Metastatic Solid Tumors
NCT03099174 This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.
NCT02057133 A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
NCT02628535 Safety Study of MGD009 in B7-H3-expressing Tumors
NCT03170960 Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03371017 A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
NCT02474173 Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
NCT03435640 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies
NCT03289962 A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
NCT02897375 Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
NCT01638533 Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
NCT03409458 A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab
NCT02124148 A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
NCT02574455 ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer
NCT03523572 Trastuzumab Deruxtecan (DS-8201a) With Nivolumab in Advanced Breast and Urothelial Cancer
NCT02900664 A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
NCT03280563 A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
NCT03435952 Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
NCT02834247 A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
NCT03330405 Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
NCT03150810 Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT02658214 Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
NCT01655225 A Study of LY3023414 in Participants With Advanced Cancer
NCT03065387 Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, HER3/4 Mutation or KRAS Mutation
NCT03129139 A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
NCT02834013 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT03601897 A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
NCT01624090 Mithramycin for Lung, Esophagus, and Other Chest Cancers
NCT02646748 Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
NCT03454451 CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers
NCT03126110 Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
NCT02677038 Olaparib for BRCAness Phenotype in Pancreatic Cancer
NCT02498613 A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
NCT01226316 Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
NCT02488967 Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02655822 Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
NCT02476955 Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
NCT03430882 TAK228 With Carbo and Taxol in Advanced Malignancies
NCT02791334 A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
NCT02892123 Trial of ZW25 in Patients With Advanced HER2-expressing Cancers
NCT03134638 A Phase 1 Study of SY-1365 in Adult Patients With Advanced Solid Tumors
NCT02922764 A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma
NCT02643303 A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers

FORCE:Facing Our Risk of Cancer Empowered